Anke Unger

1.4k total citations
24 papers, 383 citations indexed

About

Anke Unger is a scholar working on Oncology, Molecular Biology and Pharmacology. According to data from OpenAlex, Anke Unger has authored 24 papers receiving a total of 383 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 8 papers in Molecular Biology and 5 papers in Pharmacology. Recurrent topics in Anke Unger's work include Cytokine Signaling Pathways and Interactions (5 papers), Immune cells in cancer (4 papers) and Melanoma and MAPK Pathways (3 papers). Anke Unger is often cited by papers focused on Cytokine Signaling Pathways and Interactions (5 papers), Immune cells in cancer (4 papers) and Melanoma and MAPK Pathways (3 papers). Anke Unger collaborates with scholars based in Germany, Norway and United Kingdom. Anke Unger's co-authors include Markus O. Lederer, Stefan Laufer, Bert Klebl, Wolfgang Albrecht, Matthias Baumann, Jan Eickhoff, Hanife Bahsi, Corina Hutterer, Manfred Marschall and Gunther Zischinsky and has published in prestigious journals such as Angewandte Chemie International Edition, Blood and Cancer Research.

In The Last Decade

Anke Unger

22 papers receiving 380 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anke Unger Germany 12 161 85 64 53 47 24 383
Yongping Zhu China 13 247 1.5× 96 1.1× 66 1.0× 48 0.9× 66 1.4× 36 594
Siew Kwan Koh Singapore 15 261 1.6× 38 0.4× 46 0.7× 64 1.2× 35 0.7× 29 865
Ruchi Shukla India 16 439 2.7× 59 0.7× 72 1.1× 109 2.1× 43 0.9× 43 759
Robert R. Lavieri United States 11 440 2.7× 63 0.7× 60 0.9× 39 0.7× 49 1.0× 17 685
An He China 15 281 1.7× 38 0.4× 53 0.8× 23 0.4× 49 1.0× 44 501
Shuangjie Li China 11 95 0.6× 101 1.2× 39 0.6× 32 0.6× 65 1.4× 28 349
Yusheng Han United States 7 163 1.0× 24 0.3× 32 0.5× 29 0.5× 115 2.4× 9 374
Mitsuhiro Kitagawa Japan 7 245 1.5× 48 0.6× 35 0.5× 39 0.7× 12 0.3× 11 377
David F. Gebhard United States 8 226 1.4× 29 0.3× 148 2.3× 68 1.3× 46 1.0× 12 544

Countries citing papers authored by Anke Unger

Since Specialization
Citations

This map shows the geographic impact of Anke Unger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anke Unger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anke Unger more than expected).

Fields of papers citing papers by Anke Unger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anke Unger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anke Unger. The network helps show where Anke Unger may publish in the future.

Co-authorship network of co-authors of Anke Unger

This figure shows the co-authorship network connecting the top 25 collaborators of Anke Unger. A scholar is included among the top collaborators of Anke Unger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anke Unger. Anke Unger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cheng, Xiu‐Fen, Philipp Lampe, Stefano Ugel, et al.. (2025). Design, Synthesis, and Structural Evolution of Pseudo‐Natural Product IDO1 Inhibitors and Degraders. Angewandte Chemie International Edition. 65(3). e18753–e18753.
2.
Herebıan, Diran, Laura M. Levy, Haresh Ajani, et al.. (2023). Protection of pancreatic islets from oxidative cell death by a peripherally-active morphinan with increased drug safety. Molecular Metabolism. 75. 101775–101775. 1 indexed citations
3.
Eickhoff, Jan, Bert Klebl, Anke Unger, et al.. (2023). A highly selective purine-based inhibitor of CSF1R potently inhibits osteoclast differentiation. European Journal of Medicinal Chemistry. 255. 115344–115344. 7 indexed citations
4.
Unger, Anke, Peter Habenberger, Jan Eickhoff, et al.. (2023). Pyrrolopyrimidine based CSF1R inhibitors: Attempted departure from Flatland. European Journal of Medicinal Chemistry. 265. 116053–116053. 1 indexed citations
5.
Lewis, Joe, Kerstin Putzker, Ulrike Uhrig, et al.. (2023). Discovery of tetrazolo-pyridazine-based small molecules as inhibitors of MACC1-driven cancer metastasis. Biomedicine & Pharmacotherapy. 168. 115698–115698. 4 indexed citations
6.
Unger, Anke, Peter Habenberger, Alexander Wolf, et al.. (2023). Negishi Cross‐Coupling in the Preparation of Benzyl Substituted Pyrrolo[2,3‐d]pyrimidine Based CSF1R Inhibitors. European Journal of Organic Chemistry. 26(12). 4 indexed citations
7.
Meijer, Femke A., Richard G. Doveston, Anke Unger, et al.. (2021). Structure–Activity Relationship Studies of Trisubstituted Isoxazoles as Selective Allosteric Ligands for the Retinoic-Acid-Receptor-Related Orphan Receptor γt. Journal of Medicinal Chemistry. 64(13). 9238–9258. 9 indexed citations
8.
Lategahn, Jonas, Marina Keul, Hannah L. Tumbrink, et al.. (2020). Targeting Her2-insYVMA with Covalent Inhibitors—A Focused Compound Screening and Structure-Based Design Approach. Journal of Medicinal Chemistry. 63(20). 11725–11755. 12 indexed citations
9.
Falk, Sarah, et al.. (2018). Chronic high dose P2X7 receptor inhibition exacerbates cancer-induced bone pain. European Journal of Pharmacology. 845. 48–55. 15 indexed citations
10.
Rother, Marion, Matteo Pardo, Matthias Pietzke, et al.. (2018). Combined Human Genome-wide RNAi and Metabolite Analyses Identify IMPDH as a Host-Directed Target against Chlamydia Infection. Cell Host & Microbe. 23(5). 661–671.e8. 33 indexed citations
11.
Göthert, Joachim R., Michael Möllmann, Ulrich Dührsen, et al.. (2018). Potent anti-leukemic activity of a specific cyclin-dependent kinase 9 inhibitor in mouse models of chronic lymphocytic leukemia. Oncotarget. 9(41). 26353–26369. 5 indexed citations
12.
Baumann, Matthias, Heiko Müller, Anke Unger, et al.. (2018). TRPC4/TRPC5 channels mediate adverse reaction to the cancer cell cytotoxic agent (-)-Englerin A. Oncotarget. 9(51). 29634–29643. 25 indexed citations
13.
Bergbrede, Tim, Axel Choidas, Sascha Menninger, et al.. (2016). Abstract 222: Inhibitors of mitochondrial transcription (IMT) specifically affect cancer cell proliferation. Cancer Research. 76(14_Supplement). 222–222. 1 indexed citations
14.
Fehr, Sarah, et al.. (2015). Impact of p38 MAP Kinase Inhibitors on LPS-Induced Release of TNF-α in Whole Blood and Primary Cells from Different Species. Cellular Physiology and Biochemistry. 36(6). 2237–2249. 22 indexed citations
15.
Hutterer, Corina, Jan Eickhoff, Jens Milbradt, et al.. (2015). A Novel CDK7 Inhibitor of the Pyrazolotriazine Class Exerts Broad-Spectrum Antiviral Activity at Nanomolar Concentrations. Antimicrobial Agents and Chemotherapy. 59(4). 2062–2071. 92 indexed citations
16.
Richters, André, Julia Ketzer, Matthäus Getlik, et al.. (2013). Targeting Gain of Function and Resistance Mutations in Abl and KIT by Hybrid Compound Design. Journal of Medicinal Chemistry. 56(14). 5757–5772. 11 indexed citations
17.
Hauser, Dominik, et al.. (2009). 2‐Acylaminopyridin‐4‐ylimidazoles as p38 MAP Kinase Inhibitors: Design, Synthesis, and Biological and Metabolic Evaluations. ChemMedChem. 4(11). 1939–1948. 22 indexed citations
18.
Albrecht, Wolfgang, Anke Unger, Andreas K. Nüssler, & Stefan Laufer. (2008). In Vitro Metabolism of 2-[6-(4-Chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl] Acetic Acid (Licofelone, ML3000), an Inhibitor of Cyclooxygenase-1 and -2 and 5-Lipoxygenase. Drug Metabolism and Disposition. 36(5). 894–903. 11 indexed citations
19.
20.
Unger, Anke, et al.. (1971). The potentiating effect of x-irradiation on the induction of experimental tumours in mice.. PubMed. 58(4). 303–303. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yongping Zhu Breakdown of academic impact, for papers by Siew Kwan Koh Breakdown of academic impact, for papers by Ruchi Shukla Breakdown of academic impact, for papers by Robert R. Lavieri Breakdown of academic impact, for papers by An He Breakdown of academic impact, for papers by Shuangjie Li Breakdown of academic impact, for papers by Yusheng Han Breakdown of academic impact, for papers by Mitsuhiro Kitagawa Breakdown of academic impact, for papers by David F. Gebhard
Rankless by CCL
2026